Immunotherapy, a growing trend in fighting cancer and other chronic diseases

Live healthy and long

Angono, Rizal Philippines

Breakthrough of the year: Immunotherapy in Cancer cure in Science magazine


There are three modes:

1.  monoclonal antibodies that can be paired
2.  cloning T cells
3.  vaccines

There is a an article that says that in the next decade, 60% of cancer cures will come from immunotherapies. This industry will be about $35 billion.

What is immuno therapy?  It is aiding or suppressing body's immune system to fight diseases, allergies, or chronic condition.  While the body's soldiers are very effective, on their own, to locate the invaders and destroy them, the invaders protein/enzymes can fool the body's defense mechanism to ignore them.

One of the research center is that of Fred  Hutchinson  They have worked on cloning T cells to attack cancer cells, and also using radio immunotherapy (cloing antibodies with irradiated bodies, monclonal cells) to target the affected cells, which is more targetted vs. having radiation destroy both healthy and tumor cells.

Watch video of Stan Riddel, oncologiest and researcher at Fred Huthinson  cancer research center.

Read more on immunotherapy at Cancer Research Institute of America

Cancer Drug cure finally found at Stanford U School of Medicine?

Live healthy and long

From NewsMax Health | March 30, 2013 

Do you believe that cancer is untreatable?

That the cure for cancer has not been found?

This Stanford University, the center of many innovation - entrepreneurship, design school,  the origin of many Silicon Valley new business (not to mention Google) just came up with an amazing discovery -  the substance the CD 47 cancer enzyme blocker. CD 47 blocks the body's immune system from fighting cancer cells.   Cancer cells produce large amounts of CD 47 and the drug discovered at the Stanford University School of Medicine blocks this enzyme.  This is according to Irving Weissman, a Stanford U school of medicine  biologist who was interviewed by Science Magazine recently.

The antibody were found to be effective vs various cancer cells transplanted into the mice: breast, ovary, bladder, prostate, brain liver.  Having blocked the CD 47, the cancer cells are vulnerable to the body's own immune system to finish them off

Weissman added that the antibody could either:  slow down the growth of cancer cells, or prevent metastasis after the tumor has taken hold.  

The findings has been published in the Proceedings of the National Academy of Sciences published this week. And this could lead to clinical trials next year.

The research was in part funded by $20 million funding from California Institute of Regenerative Medicine